Consolidated Planning Corp’s Gilead Sciences GILD Stock Holding History

Consolidated Planning Corp’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Sell	1,937 -12	-0.6%	-$1.58K	0.03%	137
2026 Q1	$272K	Hold	1,949	–	–	0.04%	125
2025 Q4	$239K	Hold	1,949	–	–	0.02%	191
2025 Q3	$216K	Buy	1,949 +98	+5%	+$11.1K	0.02%	182
2025 Q2	$205K	Hold	1,851	–	–	0.03%	182
2025 Q1	$207K	Buy	+1,851	New	+$191K	0.03%	178
2021 Q4	–	Sell	-51	Closed	-$4K	–	211
2021 Q3	$4K	Buy	+51	New	+$3.58K	﹤0.01%	375

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Consolidated Planning Corp's GILD Position: Q2 2026 in Review

Consolidated Planning Corp reduced its Gilead Sciences (GILD) stake by 0.62% in Q2 2026, selling an estimated $1.58K and leaving 1,937 shares worth $245K. The position accounts for 0.03% of the portfolio, ranked #137.

Consolidated Planning Corp first reported a position in GILD in Q3 2021 and has held it in 7 quarters since. The position peaked at $272K in Q1 2026. 2,285 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Consolidated Planning Corp held 1,937 shares of Gilead Sciences worth $245K as of Q2 2026.
Consolidated Planning Corp sold 12 Gilead Sciences shares in Q2 2026, an estimated $1.58K.
Gilead Sciences made up 0.03% of Consolidated Planning Corp's portfolio in Q2 2026, its #137 holding.
Consolidated Planning Corp first reported a position in Gilead Sciences in Q3 2021 and has held it in 7 quarters since.
Consolidated Planning Corp's Gilead Sciences position peaked at $272K in Q1 2026.
2,285 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Consolidated Planning Corp's 13F filing for Q2 2026, filed 24 Jul 2026.